Long-term follow-up of children treated for cancer: why is it necessary, by whom, where and how?

Skinner, Roderick; Wallace, W. Hamish B.; Levitt, Gillian
March 2007
Archives of Disease in Childhood;Mar2007, Vol. 92 Issue 3, p257
Academic Journal
About 1 in 715 young adults is a survivor of childhood malignancy, but these individuals are at increased risk of considerable treatment-related morbidity or even mortality. A recent study suggests that at least 60% have one or more chronic health problems, whilst about 20% have three or more. The principle goal of long-term follow-up (LTFU) of survivors is to decrease the severity of late treatment complications by performing appropriate surveillance to detect incipient toxicity, and by facilitating timely diagnosis and management of emerging or established late adverse effects. The content of LTFU is dictated by the type and amount of treatment for the malignancy, and has been defined in recent clinical guidelines. Moreover, LTFU allows provision of survivor education, psychosocial support and health promotion advice. However, considerable variation exists in how LTFU is performed, with several alternative models involving a range of professionals in a variety of locations, depending on numerous clinical and organisational factors. There is increasing utilisation of multidisciplinary teams, and recognition of the importance of effective transition strategies whereby care is transferred to more age-appropriate providers, usually after a period of joint care in adolescence. It is of paramount importance to ascertain and meet the needs of survivors themselves.


Related Articles

  • Follow-Up Programs for Childhood Cancer Survivors in Europe: A Questionnaire Survey. Essig, Stefan; Skinner, Roderick; von der Weid, Nicolas X.; Kuehni, Claudia E.; Michel, Gisela // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: For many childhood cancer survivors follow-up care is important long after treatment completion. We aimed to describe the availability and characteristics of long-term follow-up programs (LTFU) across Europe, their content and aims, their problems, and to assess opinions on different...

  • PI-75. Skolnik, J. M.; Lee, J. I.; Barrett, J. S.; Adamson, P. C. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP26 

    Background: Actinomycin-D (Act-D) and vincristine (VCR) are used in treating pediatric cancer. Empiric dosing continues due a lack of information on drug disposition. We report a major modification to our published Act-D and VCR LC/MS/MS assay that has reduced our lower limit of quantification...

  • Review of Cardiotoxicity in Pediatric Cancer Patients: During and after Therapy. Fulbright, Joy M. // Cardiology Research & Practice;2011, p1 

    With the improvement in survival from childhood cancer, late effects of therapy are becoming more apparent. Cardiac disease, one of these late effects, has a significant impact on the life of survivors of childhood cancers. Most survivors are followed by primary care doctors and adult...

  • Intensive Chemotherapy May Improve Survival in Young Patients. McBride, Deborah // ONS Connect;Jun2008, Vol. 23 Issue 6, p8 

    The article discusses that more comprehensive chemotherapy in young patients tends to produce higher survival rates as shown in a 10-year study in young patients with neuroblastoma. Children older than age one with high-risk types of neuroblastoma were treated by the researchers and found a 12%...

  • Cancer Kills Children Too. Spencer, Steven M. // Saturday Evening Post;4/28/1951, Vol. 223 Issue 44, p32 

    The article focuses on cancer in children. Cancer is a major cause of death in the U.S. among children five to fourteen years of age. The hopeless attitude towards cancer in children causes delay in seeking treatment that might save a child's life. It emphasized that general lack of awareness...

  • Clinical Experience with Nimotuzumab in Cuban Pediatric Patients with Brain Tumors, 2005 to 2007. Saurez, Giselle; Cabanas, Ricardo; Zaldívar, Melba; Garnier, Tania; Iglesias, Bárbara; Piedra, Patricia; Castillo, Martha Ríos; Longchong, Martha; Iznaga, Normando; Lage, Agustín // MEDICC Review;Summer2009, Vol. 11 Issue 3, p27 

    Introduction Nimotuzumab, developed in Cuba, is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It has been evaluated in malignant brain tumors in adults and children, and shown to be therapeutically safe and effective in terms of increased survival and...

  • Predicting and Modifying Substance Use in Childhood Cancer Survivors: Application of a Conceptual Model. Cox, Cheryl L.; McLaughlin, Rosemary A.; Steen, Brenda D.; Hudson, Melissa M. // Oncology Nursing Forum;Jan2006, Vol. 33 Issue 1, p51 

    Purpose/Objectives: To identify factors that predict or modify substance use in childhood cancer survivors and to describe how a risk-counseling intervention reduced young survivors' substance use. Design: Secondary analysis of clinical trial data and primary analysis of medical record data....

  • PARENTS' EXPERIENCES WITH CANCER TREATMENT DECISION MAKING. Stewart, Janet; Pyke-Grimm, Kimberly; Kelly, Katherine // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p232 

    Pediatric oncology nurses play a crucial role in supporting parents in major treatment decisions for their children with cancer, one of the most stressful challenges parents face. The purpose of this study is to learn more about how parents of children with cancer participate in major treatment...

  • Cancer death rates continue to drop in U.S.  // Dermatology Times;Oct2006, Vol. 27 Issue 10, p27 

    The article reports that cancer death rates have continued to drop in the U.S. According to the statistics, cancer death rates have declined to 11 of the 15 common cancers of men, and 10 of the 15 common cancers of women. Accordingly, the researchers pointed factors that minimized cancer death...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics